Key facts
- Wheeler Bio’s last known valuation is $83.0M (May 2023).
- It has raised $81.0M across 3 recorded rounds; the latest was Early Stage VC ($23.1M) in Mar 2025.
- Notable investors include Floating Point, Carnrite Ventures, Echo Investment Capital, Presbyterian Health Foundation, ATUM (Biotechnology) — 14 tracked in total.
- Wheeler Bio has filed 3 Form Ds with the SEC since 2021, most recently Apr 2025 ($23.1M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Wheeler Bio
Funding rounds
3 roundsAbout Wheeler Bio
Developer of a biomanufacturing service intended to accelerate the translation of therapeutic innovations into clinical impact. The company services avoid the critical gaps between discovery and early development and provide access to rapid, quality biomanufacturing that aligns with different stages of development, enabling pharmaceutical companies to streamline their drug development processes.
- Sector
- Healthcare
- HQ
- Oklahoma City, OK, United States
- Founded
- 2020
- Employees
- 74
- Website
- wheelerbio.com/
- Ownership
- Privately Held (backing)
Wheeler Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Wheeler Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Wheeler Bio in its N-PORT filings yet. We sweep new filings monthly.